Healthcare
Rallybio Corporation(RLYB)
Live Price
Offline$15.97
+0.31% today
1Y Change
+537.82%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $50.00M
- Revenue Growth
- +34.9%
- EPS Growth
- +85.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rallybio Corporation (RLYB) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $15.97 and up 537.8% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +34.9%, EPS growth of +85.1%, a dividend yield of 0.0%. What stands out right now is revenue +34.9%, EPS +85.1%, free cash flow +39.5% with operating margin -3853.6% and ROIC -56.9%. Valuation already assumes a fairly strong business story at price/sales 58.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLYB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+34.9% vs +7.6% peer median
Operating Margin
Below sector median
-3853.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +34.9% and EPS at +85.1%, with operating margin around -3853.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +2.3% | +1.1% | +13.6% |
2026 Mar 12, 2026 | +0.0% | -1.0% | -5.3% | -12.1% |
2025 Nov 6, 2025 | +44.0% | -2.2% | +2.7% | +3.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLYB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RLYB Max Drawdown
-31.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RLYB and SPY.
Company Overview
Rallybio Corporation
NASDAQ Capital Market
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
- Leadership
- Stephen Uden
- IPO Date
- Jul 29, 2021
- Employees
- 15
- Street Address
- 234 Church Street
- Mailing
- New Haven, CT, 06510
- Region
- New Haven, CT, US
- Reporting Currency
- USD
- Investor Line
- 203 859 3820
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 58.0
- Price/Book
- 0.9
Growth
- Revenue
- +34.9%
- EPS
- +85.1%
- Free Cash Flow
- +39.5%
Profitability
- Gross Margin
- 99.7%
- Operating Margin
- -3853.6%
- Net Margin
- -1046.4%
- ROE
- -16.2%
- ROIC
- -56.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 14.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.